C7R.CD30.CAR-EBVST

C7R.CD30.CAR-EBVST is an advanced cell therapy product that combines several therapeutic elements to target CD30-positive lymphomas. This therapy represents a significant advancement in off-the-shelf adoptive T cell therapies, designed to overcome challenges like graft-versus-host disease and graft rejection. ## Composition and Mechanism C7R.CD30.CAR-EBVST consists of Epstein-Barr virus-specific T cells (EBVSTs) that have been genetically modified to express: 1. A chimeric antigen receptor (CAR) targeting CD30, a transmembrane protein expressed on various lymphomas 2. A constitutive IL-7 receptor (C7R) molecule that enhances the persistence and anti-cancer effects of the CAR T cells 3. An iC9 safety switch marker that allows for elimination of the cells if intolerable side effects occur The CD30.CAR component enables the T cells to recognize and attack CD30-positive tumor cells. When CD30 on tumor cells binds to the CAR, it triggers signaling pathways that activate the T cells to kill the tumor cells[1][6]. The C7R modification is designed to extend the anti-cancer effects of the CD30.CAR T cells, making them more effective and longer-lasting[5]. The EBVSTs provide a platform that avoids graft-versus-host disease, which has been demonstrated in several clinical trials[1]. Additionally, the CD30.CAR can target alloreactive T cells that upregulate CD30 upon activation, helping to prevent graft rejection[1]. ## Clinical Development This therapy is currently being evaluated in a dose escalation clinical trial for patients with CD30-positive lymphomas that have relapsed or are refractory to standard treatments[5]. The trial is designed to: 1. Study the safety and effectiveness of the C7R.CD30.CAR-EBVST cells 2. Determine the optimal dosing level (testing 4 different dose levels) 3. Evaluate side effects and clinical responses Preliminary results from related trials using CD30.CAR-EBVSTs (without the C7R modification) have shown promising clinical activity with no significant safety concerns[5][7]. ## Advantages The key advantages of this therapy include: - Immediate availability as an "off-the-shelf" product - Reduced manufacturing time compared to autologous CAR T therapies - Potential for deeper and longer anti-cancer effects due to the C7R modification - Built-in safety mechanism (iC9) that allows for elimination of the cells if needed - Ability to target CD30, which is expressed in various lymphomas including Hodgkin lymphoma This innovative approach represents a significant advancement in the field of adoptive cell therapy for lymphomas, particularly for patients who have exhausted other treatment options.

Other names

Constitutive IL7R Modified Banked Allogeneic CD30.CAR-EBVST